Login to Your Account

FDA: Celator's ASCO exhibit stepped over the OPDP line

By Mari Serebrov
Regulatory Editor

Tuesday, September 6, 2016

In its third letter of the year, the FDA's Office of Prescription Drug Promotion came down on Celator Pharmaceuticals Inc. for promoting a promising but yet-to-be-approved cancer drug in an exhibit at the ASCO annual meeting in June.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription